Claims for Patent: 11,554,229

Summary for Patent: 11,554,229

Title:	Nasal administration
Abstract:	A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.
Inventor(s):	Per Gisle Djupesland, Ramy A. Mahmoud, John Messina
Assignee:	Optinose Inc
Application Number:	US14/315,132
Patent Claims:	1. A method of treating nasal polyps in a patient comprising: placing a nosepiece into a first nostril of the patient; placing a mouthpiece into a mouth of the patient, the mouthpiece being fluidly connected to the nosepiece, wherein exhalation by the patient into the mouthpiece and out of the nosepiece produces a bi-directional fluid flow of exhalation air into a first nasal passageway of the patient and out of a second nasal passageway of the patient; administering fluticasone during exhalation by the patient through the nosepiece; delivering carbon dioxide during exhalation by the patient through the nosepiece, to a location at an upper posterior region of the first nasal passageway of the patient; and reducing a pH at the location at the upper posterior region of the first nasal passageway of the patient by an amount ranging from about 0.1 pH units to about 0.2 pH units by controlling the fluid flow to deliver the carbon dioxide at a concentration of from about 5% vol/vol to about 6% vol/vol carbon dioxide and at a fluid flow rate of at least 20 L/min for a duration of from about 2 seconds to about 3 seconds, wherein the carbon dioxide is delivered before or at the same time as the fluticasone. 2. The method of claim 1, wherein the fluticasone is fluticasone propionate. 3. The method of claim 1, wherein the fluticasone is administered as a liquid aerosol. 4. The method of claim 1, wherein the fluticasone is administered in an amount of about 400 μg b.i.d. 5. The method of claim 1, wherein the fluticasone is administered in an amount of 100 μg to 400 μg b.i.d. 6. The method of claim 1, wherein the fluticasone is administered in an amount of at least 200 μg daily. 7. The method of claim 1, wherein the fluticasone is administered in an amount of at least 400 μg daily. 8. The method of claim 1, wherein the fluticasone is administered in an amount of at least 200 μg daily delivered in two doses. 9. The method of claim 1, wherein the fluticasone is administered in an amount of at least 400 μg daily delivered in two doses. 10. The method of claim 1, wherein the fluticasone is fluticasone propionate administered as a liquid aerosol in an amount of 100 μg to 400 μg b.i.d. 11. The method of claim 1, wherein the fluticasone is fluticasone propionate administered as a liquid aerosol in an amount of at least 200 μg b.i.d. 12. A method of treating chronic rhinosinusitis with or without nasal polyps in a patient comprising: placing a nosepiece into a first nostril of the patient; placing a mouthpiece into a mouth of the patient, the mouthpiece being fluidly connected to the nosepiece, wherein exhalation by the patient into the mouthpiece and out of the nosepiece produces a bi-directional fluid flow of exhalation air into a first nasal passageway of the patient and out of a second nasal passageway of the patient; administering fluticasone during exhalation by the patient through the nosepiece; delivering carbon dioxide during exhalation by the patient through the nosepiece, to a location at an upper posterior region of the first nasal passageway of the patient; and reducing a pH at the location at the upper posterior region of the first nasal passageway of the patient by an amount ranging from about 0.1 pH units to about 0.2 pH units by controlling the fluid flow to deliver the carbon dioxide at a concentration of from about 5% vol/vol to about 6% vol/vol carbon dioxide and at a fluid flow rate of at least 20 L/min for a duration of from about 2 seconds to about 3 seconds, wherein the carbon dioxide is delivered before or at the same time as the fluticasone. 13. The method of claim 12, wherein the fluticasone is fluticasone propionate. 14. The method of claim 12, wherein the fluticasone propionate is administered as a liquid aerosol. 15. The method of claim 12, wherein the fluticasone propionate is administered in an amount of about 400 μg b.i.d. 16. The method of claim 13, wherein the fluticasone is administered in an amount of 100 μg to 400 μg b.i.d. 17. The method of claim 13, wherein the fluticasone is administered in an amount of at least 200 μg daily. 18. The method of claim 13, wherein the fluticasone is administered in an amount of at least 400 μg daily. 19. The method of claim 13, wherein the fluticasone is administered in an amount of at least 200 μg daily delivered in two doses. 20. The method of claim 13, wherein the fluticasone is administered in an amount of at least 400 μg daily delivered in two doses. 21. The method of claim 13, wherein the fluticasone is fluticasone propionate administered as a liquid aerosol in an amount of 100 μg to 400 μg b.i.d. 22. The method of claim 13, wherein the fluticasone is fluticasone propionate administered as a liquid aerosol in an amount of at least 200 μg b.i.d.